New landscape of the diagnosis of Alzheimer's disease
University of Southern California · Washington University in St. Louis · +3 more institutions
Abstract
Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to…
Citation impact
- FWCI
- 63.86
- Percentile
- 100%
- References
- 198
Authors
18Topics & keywords
- Disease
- Differential diagnosis
- Diagnostic test
- Health care
- MEDLINE
- Patient care
- Differential (mechanical device)
Funding
- AAAlzheimer's AssociationAwards: AARG 2019-AARG-644641-RAPID, AARG 2019-AARG-644641, 2019-AARG-644641
- ELEli Lilly and Company
- UOUniversity of California
- BBiogen
- BFBrightFocus Foundation
- DDanone
- HHealth~HollandAward: LSHM20106
- RNRoche Nederland
- UCUniversity College London
- ECEuropean CommissionAwards: 101132933, 101112145
- ZZonMwAwards: 10510032120003, 73305095007
- GDGeneralitat de CatalunyaAward: PID2019
- EEisai
- NNNovo Nordisk
- UDUniversità degli Studi di Genova
- MDMinisterio de Ciencia e InnovaciónAwards: PID2019, PID2019-111514RA-I00
- UDUniversité de Genève
- HHersenstichting
- SDStichting Dioraphte
- ANAlzheimer NederlandAward: LSHM20106
- HLH. Lundbeck A/S
- FAFONDATION ALZHEIMER
- GGrifols
- EBEuropean Brain Council
- NINational Institutes of Health
- IDInstituto de Salud Carlos III
- UPUCB Pharma